Brind.

Expert joins company leading development of influenza preventative medicine

2 reports, 1 independent Updated Oct 6
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Dr Koh brings extensive infectious disease and clinical development expertise to RQ Bio as the company advances RQB01 into the clinic. His background includes senior roles at both GSK and AstraZeneca, where he led programs from discovery to registration and launch. Additionally, Dr Koh serves as an Honorary Consultant in the UK’s National Health Service (NHS).

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The appointment comes following RQ Bio secured $115 million in Series A financing. Dr Koh’s experience is focused on helping the company execute the clinical development of RQB01. This move strengthens the company's capabilities in developing preventative medicines against influenza.

From manilatimes.net

Who's involved

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story